Centurion Labs Issues Voluntary Nationwide Recall of Certain Lots of Ninjacof and Ninjacof A
Centurion Labs is voluntarily recalling, as a precautionary measure, one lot of Ninjacof (Lot# 200N1601) and one lot of Ninjacof A (Lot# 201NA1601) manufactured by Vilvet (Dania Beach, FL) and distributed by Centurion Labs to the retail level due to potential contamination with Burkholderia cepacia. Centurion was notified by the FDA regarding the potential contamination as they discovered this product may have been manufactured in a Pharmatech, FDA registered facility, in Davie, FL that was found to have a product that contained B. cepacia.
Use of a product that may contain B. cepacia, could result in infections in patients with compromised immune systems and in patients with chronic lung conditions such as cystic fibrosis. Some of these infections may be serious or even life threatening in the at-risk patient population.
Ninjacof and Ninjacof A are used to temporarily relieve symptoms due to the common cold, allergic rhinitis, or other respiratory allergies. The products are sold in 473 mL bottles with the expiration date of 11/2018. The affected products are Ninjacof with Lot# 200N1601 (NDC 23359-032-16) and Ninjacof A with Lot# 201NA1601 (NDC 23359-033-16). Both were distributed within the following states: Alabama, Arkansas, Florida, Georgia, Louisiana, Missouri, Mississippi, New Jersey, North Carolina, Ohio, Oklahoma, South Carolina, Tennessee, and Texas.
Centurion Labs is notifying its distributors and customers by recall letter. To date Centurion Labs has not found any B. cepacia or received any complaints for the products or lots listed. However, it is recommended that patients, pharmacies, and healthcare facilities that have the recalled product on hand stop their use immediately.
Consumers with questions regarding this recall can contact the company at Centurion Customer Support: firstname.lastname@example.org or 601-852-3681 (M-F 8am – 5pm Central Standard Time).
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program.
Want to read the full alert and receive alert emails?